Loading clinical trials...
Loading clinical trials...
A 2-Part Study to Evaluate the Relative Bioavailability of 2 New Formulations of UCB0599 and the Effect of Esomeprazole on the PK of UCB0599 in Healthy Participants (Part A, Open-Label) and to Assess the Safety/Tolerability and PK of UCB0599 in Healthy Participants of Japanese and Chinese Origins (Part B, Double-Blind)
Conditions
Interventions
UCB0599
Esomeprazole
+1 more
Locations
1
United States
Up0073 10001
Glendale, California, United States
Start Date
May 31, 2023
Primary Completion Date
April 13, 2024
Completion Date
April 13, 2024
Last Updated
December 22, 2025
NCT06679413
NCT04867642
NCT05292131
NCT04828343
NCT04444466
NCT04136444
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions